Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

GSK Continues R&D Externalization With Option To License Kinase Inhibitors

  • News

Executive Summary

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at 1http://invivoblog.blogspot.com/.

You may also be interested in...



Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors

Exelixis cashes in on a hot therapeutic drug target, showing that an R&D-focused biotech can succeed in the marketplace.

GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis

GlaxoSmithKline's creation of a separate "GSK Oncology" R&D unit is not only intended to capture efficiency and strengthen its position in the crowded field - the firm is also aiming to further its personalized medicine research

GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis

GlaxoSmithKline's creation of a separate "GSK Oncology" R&D unit is not only intended to capture efficiency and strengthen its position in the crowded field - the firm is also aiming to further its personalized medicine research

Table

View full table

Tags:
UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By